David Hur, MD, director of structural heart disease/interventional imaging at the VA Connecticut Healthcare System, and an assistant professor of medicine at Yale, explains the technical challenges encountered in cardiac computed tomography (CT) and how to overcome them.

The contrast agent, simply called Gadobutrol Injection, has been approved by the U.S. Food and Drug Administration and is now available in the United States.

According to a new SCAI statement, the FDA's recommendation would result in "far-reaching consequences" across multiple specialties. 

Brian Ghoshhajra, MD, MBA, division chief, cardiovascular imaging, Massachusetts General Hospital and associate professor of radiology, Harvard Medical School, explains the impact of the iodine contrast shortage on computed tomography (CT) and cardiac imaging.
 

Production at the facility in Shanghai is expected to be near 100% starting on June 6.

The American College of Radiology (ACR) announced this week its government relations staff has been engaging federal agencies in an effort to improve product availability and hasten resolution of the ongoing iodine contrast shortage.

Alan Matsumoto, MD, chair of the department of radiology at the University of Virginia and vice chair of the ACR Board of Chancellors, explains how the ACR and group purchasing organizations are asking the FDA to mitigate the contrast shortage with an emergency use authorization to allow non-FDA cleared iodine contrast agents to be imported.

Eric Williamson, MD, president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging and ways this can be mitigated.